MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, SLNCF made $159K in revenue. -$20,958K in net income. Net profit margin of -13181.13%.

Income Overview

Revenue
$159K
Net Income
-$20,958K
Net Profit Margin
-13181.13%
EPS
-$0.15
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
Revenue
159
Cost of sales
64
Gross profit
95
Research and development costs
20,544
General and administrative expenses
5,795
Restructuring charges
0
Operating loss
-26,244
Foreign currency gain/(loss), net
1,934
Other income, net
770
Benefit from r&d credit
2,583
Loss before income tax expense
-20,957
Income tax expense
1
Net loss
-20,958
Earnings per share, basic
-0.15
Earnings per share, diluted
-0.15
Weighted average number of shares outstanding, basic
141,701,848
Weighted average number of shares outstanding, diluted
141,701,848
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$20,958K Income tax expense$1K Loss before incometax expense-$20,957K Benefit from r&d credit$2,583K Other income, net$770K Foreign currencygain/(loss), net$1,934K Revenue$159K Operating loss-$26,244K Gross profit$95K Cost of sales$64K General andadministrative expenses$5,795K Research and developmentcosts$20,544K

Silence Therapeutics plc (SLNCF)

Silence Therapeutics plc (SLNCF)